146 related articles for article (PubMed ID: 18091385)
1. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique.
Plaza JA; Suster D; Perez-Montiel D
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):421-5. PubMed ID: 18091385
[TBL] [Abstract][Full Text] [Related]
2. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
3. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases.
Romano RC; Carter JM; Folpe AL
Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451
[TBL] [Abstract][Full Text] [Related]
4. A metastatic melanoma with an unusual immunophenotypic profile.
Gao Z; Stanek A; Chen S
Am J Dermatopathol; 2007 Apr; 29(2):169-71. PubMed ID: 17414440
[TBL] [Abstract][Full Text] [Related]
5. Expression of melanoma antigens in epithelioid gastrointestinal stromal tumors: a potential diagnostic pitfall.
Guler ML; Daniels JA; Abraham SC; Montgomery EA
Arch Pathol Lab Med; 2008 Aug; 132(8):1302-6. PubMed ID: 18684030
[TBL] [Abstract][Full Text] [Related]
6. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of melanocytic differentiation antigens in cutaneous malignant melanoma. A comparison of six commercial antibodies and one non-commercial antibody in nodular melanoma, superficially spreading melanoma and lentigo maligna melanoma.
Kocan P; Jurkovic I; Böör A; Dudríková K; Krajcár R; Benický M; Kromydaki A
Cesk Patol; 2004 Apr; 40(2):50-6. PubMed ID: 15233017
[TBL] [Abstract][Full Text] [Related]
8. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
Hitzer S; Bialasiewicz AA; Richard G
Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
[TBL] [Abstract][Full Text] [Related]
10. Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers.
Guo R; Franco-Palacios M; Russell M; Goddard L; Hassell L; Gillies E; Fung KM
Int J Clin Exp Pathol; 2013; 6(8):1658-64. PubMed ID: 23923085
[TBL] [Abstract][Full Text] [Related]
11. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
12. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
13. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
14. Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.
Viray H; Bradley WR; Schalper KA; Rimm DL; Gould Rothberg BE
Arch Pathol Lab Med; 2013 Aug; 137(8):1063-73. PubMed ID: 23899062
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors.
Zhang H; Bu H; Chen H; Wei B; Liu W; Guo J; Li F; Liao D; Tang Y; Zhang Z
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):32-9. PubMed ID: 18091323
[TBL] [Abstract][Full Text] [Related]
17. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum.
Plaza JA; Torres-Cabala C; Evans H; Diwan HA; Suster S; Prieto VG
Am J Dermatopathol; 2010 Apr; 32(2):129-36. PubMed ID: 20010406
[TBL] [Abstract][Full Text] [Related]
19. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
20. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]